{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Fucose-mannose ligand", "Glycyrrhizin", "Macrophage", "Nitric oxide", "Visceral leishmaniasis"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32690108", "DateCompleted": {"Year": "2021", "Month": "03", "Day": "16"}, "DateRevised": {"Year": "2021", "Month": "03", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "07", "Day": "20"}], "Language": ["eng"], "ELocationID": ["363", "10.1186/s13071-020-04243-7"], "Journal": {"ISSN": "1756-3305", "JournalIssue": {"Volume": "13", "Issue": "1", "PubDate": {"Year": "2020", "Month": "Jul", "Day": "20"}}, "Title": "Parasites & vectors", "ISOAbbreviation": "Parasit Vectors"}, "ArticleTitle": "Cytokine profile and nitric oxide levels in peritoneal macrophages of BALB/c mice exposed to the fucose-mannose ligand of Leishmania infantum combined with glycyrrhizin.", "Pagination": {"StartPage": "363", "MedlinePgn": "363"}, "Abstract": {"AbstractText": ["The fucose-mannose ligand (FML) of Leishmania infantum is a complex glycoprotein which does not elicit adequate immunogenicity in humans. In recent years, adjuvant compounds derived from plants have been used for improving the immunogenicity of vaccines. Glycyrrhizin (GL) is a natural triterpenoid saponin that has known immunomodulatory activities. In the present study, we investigated the effects of co-treatment with FML and GL on the production of cytokines and nitric oxide (NO) by macrophages, in vitro.", "Lipopolysaccharide (LPS) stimulated murine peritoneal macrophages were treated with FML (5\u00a0\u03bcg/ml) of L. infantum and various concentrations of GL (1\u00a0\u03bcg/ml, 10 \u03bcg/ml and 20 \u03bcg/ml). After 48 h of treatment, cell culture supernatants were recovered and the levels of TNF-\u03b1, IL-10, IL-12p70 and IP-10 were measured by sandwich ELISA and NO concentration by Griess reaction.", "Our results indicate that the treatment of activated macrophages with FML plus GL leads to enhanced production of NO, TNF-\u03b1 and IL-12p70, and reduction of IL-10 levels in comparison with FML treatment alone.", "Therefore, we concluded that GL can improve the immunostimulatory effect of FML on macrophages and leads to their polarization towards an M1-like phenotype."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products & Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran."}], "LastName": "Namdar Ahmadabad", "ForeName": "Hasan", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Vector-borne Diseases Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran. reza_shafi@yahoo.com."}], "LastName": "Shafiei", "ForeName": "Reza", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Parasitology and Mycology, Shiraz University of Medical Sciences, Shiraz, Iran."}], "LastName": "Hatam", "ForeName": "Gholam Reza", "Initials": "GR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Energy and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), 14965/161, Tehran, Iran."}], "LastName": "Zolfaghari Emameh", "ForeName": "Reza", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Medicine and Health Technology, Tampere University, 33014, Tampere, Finland."}], "LastName": "Aspatwar", "ForeName": "Ashok", "Initials": "A"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Parasit Vectors", "NlmUniqueID": "101462774", "ISSNLinking": "1756-3305"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Adjuvants, Immunologic"}, {"RegistryNumber": "0", "NameOfSubstance": "Antigens, Protozoan"}, {"RegistryNumber": "0", "NameOfSubstance": "Cytokines"}, {"RegistryNumber": "0", "NameOfSubstance": "Drug Combinations"}, {"RegistryNumber": "0", "NameOfSubstance": "Lectins"}, {"RegistryNumber": "0", "NameOfSubstance": "Leishmaniasis Vaccines"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Necrosis Factor-alpha"}, {"RegistryNumber": "0", "NameOfSubstance": "fucose-binding lectin"}, {"RegistryNumber": "130068-27-8", "NameOfSubstance": "Interleukin-10"}, {"RegistryNumber": "187348-17-0", "NameOfSubstance": "Interleukin-12"}, {"RegistryNumber": "31C4KY9ESH", "NameOfSubstance": "Nitric Oxide"}, {"RegistryNumber": "6FO62043WK", "NameOfSubstance": "Glycyrrhizic Acid"}], "MeshHeadingList": [{"QualifierName": ["pharmacology"], "DescriptorName": "Adjuvants, Immunologic"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["immunology"], "DescriptorName": "Antigens, Protozoan"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cytokines"}, {"QualifierName": [], "DescriptorName": "Drug Combinations"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Glycyrrhizic Acid"}, {"QualifierName": ["metabolism"], "DescriptorName": "Interleukin-10"}, {"QualifierName": ["metabolism"], "DescriptorName": "Interleukin-12"}, {"QualifierName": ["metabolism", "pharmacology"], "DescriptorName": "Lectins"}, {"QualifierName": ["metabolism"], "DescriptorName": "Leishmania infantum"}, {"QualifierName": ["chemistry"], "DescriptorName": "Leishmaniasis Vaccines"}, {"QualifierName": ["immunology"], "DescriptorName": "Leishmaniasis, Visceral"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Macrophages, Peritoneal"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": ["immunology"], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": ["metabolism"], "DescriptorName": "Nitric Oxide"}, {"QualifierName": ["metabolism"], "DescriptorName": "Tumor Necrosis Factor-alpha"}], "CoiStatement": "The authors declare that they have no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Barani S, Turki H, Shafiei R, Jafarzadeh F, Hosseinzadeh Maleki H, Raeghi S. Clinico-hematological findings of acute pediatric visceral leishmaniasis referred to the northeast of Iran during 2005\u20132015. Iran J Parasitol. 2020;15:214\u2013222.", "ArticleIdList": ["PMC7311815", "32595711"]}, {"Citation": "Mirahmadi H, Mansouri Nia M, Ebrahimzadeh A, Mehravaran A, Shafiei R, Rahimi MT, et al. Genotyping determination of Acanthamoeba strains: an original study and a systematic review in Iran. J Water Health. 2019;17:717\u2013727. doi: 10.2166/wh.2019.048.", "ArticleIdList": ["10.2166/wh.2019.048", "31638023"]}, {"Citation": "Shafiei R, Ghatee MA, Jafarzadeh F, Javanshir Z, Karamian M. Genotyping and phylogenetic analysis of unusually located hydatid cysts isolated from humans in north-east Iran. J Helminthol. 2019;94:e64. doi: 10.1017/S0022149X19000579.", "ArticleIdList": ["10.1017/S0022149X19000579", "31331413"]}, {"Citation": "Sarkari B, Parhoode M, Khabisi SA, Shafiei R, Mohammadi-ghalehbin B. Genetic diversity of Fasciola spp. isolates from northern part of Iran: comparison with southwestern isolates. J Parasit Dis. 2017;41:768\u201372.", "ArticleIdList": ["PMC5555931", "28848276"]}, {"Citation": "Sarkari B, Lari M, Shafiei R, Sadjjadi SM. A comparative seroprevalence study of toxocariasis in hypereosinophilic and apparently healthy individuals. Arch Pediatr Infect Dis. 2015;3:e17911."}, {"Citation": "Ponte-Sucre A, Gamarro F, Dujardin J-C, Barrett MP, L\u00f3pez-V\u00e9lez R, Garc\u00eda-Hern\u00e1ndez R, et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS neglected tropical diseases. 2017;11:e0006052. doi: 10.1371/journal.pntd.0006052.", "ArticleIdList": ["10.1371/journal.pntd.0006052", "PMC5730103", "29240765"]}, {"Citation": "Moafi M, Rezvan H, Sherkat R, Taleban R. Leishmania vaccines entered in clinical trials: a review of literature. Int J Prev Med. 2019;10:95. doi: 10.4103/ijpvm.IJPVM_116_18.", "ArticleIdList": ["10.4103/ijpvm.IJPVM_116_18", "PMC6592111", "31360342"]}, {"Citation": "Chakravarty JKS, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011;29:3531\u20133537. doi: 10.1016/j.vaccine.2011.02.096.", "ArticleIdList": ["10.1016/j.vaccine.2011.02.096", "21414377"]}, {"Citation": "Jain K, Jain NK. Vaccines for visceral leishmaniasis: a review. J Immunol Methods. 2015;422:1\u201312. doi: 10.1016/j.jim.2015.03.017.", "ArticleIdList": ["10.1016/j.jim.2015.03.017", "25858230"]}, {"Citation": "Duarte MC, Lage DP, Martins VT, Chavez-Fumagalli MA, Roatt BM, Menezes-Souza D, et al. Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis. Rev Soc Bras Med Trop. 2016;49:398\u2013407. doi: 10.1590/0037-8682-0120-2016.", "ArticleIdList": ["10.1590/0037-8682-0120-2016", "27598624"]}, {"Citation": "Evans KJ, Kedzierski L. Development of vaccines against visceral leishmaniasis. J Trop Med. 2012;2012:892817. doi: 10.1155/2012/892817.", "ArticleIdList": ["10.1155/2012/892817", "PMC3170777", "21912561"]}, {"Citation": "Zolfaghari Emameh R, Barker H, Hytonen VP, Tolvanen ME, Parkkila S. Beta carbonic anhydrases: novel targets for pesticides and anti-parasitic agents in agriculture and livestock husbandry. Parasit Vectors. 2014;7:403. doi: 10.1186/1756-3305-7-403.", "ArticleIdList": ["10.1186/1756-3305-7-403", "PMC4162934", "25174433"]}, {"Citation": "Das A, Ali N. Vaccine development against Leishmania donovani. Front Immunol. 2012;3:99. doi: 10.3389/fimmu.2012.00099.", "ArticleIdList": ["10.3389/fimmu.2012.00099", "PMC3351671", "22615707"]}, {"Citation": "Saraiva EM dFBA, Santos FN, Borja-Cabrera GP, Nico D, Souza LO, de Oliveira Mendes-Aguiar C, et al. The FML vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine. 2006;24:2423\u201331.", "ArticleIdList": ["16386824"]}, {"Citation": "Palatnik-de-Sousa C, Dutra H, Borojevic R. Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the fucose-mannose ligand (FML) Acta Trop. 1993;53:59\u201372. doi: 10.1016/0001-706X(93)90006-W.", "ArticleIdList": ["10.1016/0001-706X(93)90006-W", "8096110"]}, {"Citation": "Tomiotto-Pellissier F, da Silva Bortoleti BT, Assolini JP, Gon\u00e7alves MD, Carloto ACM, Miranda-Sapla MM, et al. Macrophage polarization in leishmaniasis: broadening horizons. Front Immunol. 2018;9:2529. doi: 10.3389/fimmu.2018.02529.", "ArticleIdList": ["10.3389/fimmu.2018.02529", "PMC6220043", "30429856"]}, {"Citation": "Faraji F, Karjoo Z, Moghaddam MV, Heidari S, Emameh RZ, Falak R. Challenges related to the immunogenicity of parenteral recombinant proteins: underlying mechanisms and new approaches to overcome it. Int Rev Immunol. 2018;37:301\u2013315. doi: 10.1080/08830185.2018.1471139.", "ArticleIdList": ["10.1080/08830185.2018.1471139", "29851534"]}, {"Citation": "Shafiei R, Namdar Ahmadabad H, Nezafat Ferizi M, Bakhshi Joibari F, Ghahramani A, Hatam GR, et al. Cytokine profile and nitric oxide levels in macrophages exposed to Leishmania infantum FML. Exp Parasitol. 2019;203:1\u20137. doi: 10.1016/j.exppara.2019.05.004.", "ArticleIdList": ["10.1016/j.exppara.2019.05.004", "31128104"]}, {"Citation": "Bordbar N, Karimi MH, Amirghofran Z. The effect of glycyrrhizin on maturation and T cell stimulating activity of dendritic cells. Cell Immunol. 2012;280:44\u201349. doi: 10.1016/j.cellimm.2012.11.013.", "ArticleIdList": ["10.1016/j.cellimm.2012.11.013", "23261828"]}, {"Citation": "Yamashita T, Asano Y, Taniguchi T, Nakamura K, Saigusa R, Miura S, et al. Glycyrrhizin ameliorates fibrosis, vasculopathy, and inflammation in animal models of systemic sclerosis. J Invest Dermatol. 2017;137:631\u2013640. doi: 10.1016/j.jid.2016.08.037.", "ArticleIdList": ["10.1016/j.jid.2016.08.037", "PMC5380226", "27777101"]}, {"Citation": "Yoshida S, Lee JO, Nakamura K, Suzuki S, Hendon DN, Kobayashi M, et al. Effect of glycyrrhizin on pseudomonal skin infections in human-mouse chimeras. PLoS One. 2014;9:e83747. doi: 10.1371/journal.pone.0083747.", "ArticleIdList": ["10.1371/journal.pone.0083747", "PMC3907411", "24497916"]}, {"Citation": "Deng QP, Wang MJ, Zeng X, Chen GG, Huang RY. Effects of glycyrrhizin in a mouse model of lung adenocarcinoma. Cell Physiol Biochem. 2017;41:1383\u20131392. doi: 10.1159/000467897.", "ArticleIdList": ["10.1159/000467897", "28315871"]}, {"Citation": "Dai JH, Iwatani Y, Ishida T, Terunuma H, Kasai H, Iwakula Y, et al. Glycyrrhizin enhances interleukin-12 production in peritoneal macrophages. Immunology. 2001;103:235\u2013243. doi: 10.1046/j.1365-2567.2001.01224.x.", "ArticleIdList": ["10.1046/j.1365-2567.2001.01224.x", "PMC1783229", "11412311"]}, {"Citation": "Yi H, Nakashima I, Isobe K. Enhancement of nitric oxide production from activated macrophages by glycyrrhizin. Am J Chin Med. 1996;24:271\u2013278. doi: 10.1142/S0192415X96000335.", "ArticleIdList": ["10.1142/S0192415X96000335", "8982439"]}, {"Citation": "Foroughi-Parvar F, Hatam GR, Sarkari B, Kamali-Sarvestani E. Leishmania infantum FML pulsed-dendritic cells induce a protective immune response in murine visceral leishmaniasis. Immunotherapy. 2015;7:3\u201312. doi: 10.2217/imt.14.102.", "ArticleIdList": ["10.2217/imt.14.102", "25572475"]}, {"Citation": "Bibak B, Gharib FG, Daneshmandi S, Abbaspour AR, Firizi MN, Ahmadabad HN. The immunomodulatory effects of abortion-prone mice decidual and serum soluble factors on macrophages and splenocytes. Eur J Obstet Gynecol Reprod Biol. 2012;165:331\u2013336. doi: 10.1016/j.ejogrb.2012.08.006.", "ArticleIdList": ["10.1016/j.ejogrb.2012.08.006", "22940120"]}, {"Citation": "de Lima VM, Ikeda FA, Rossi CN, Feitosa MM, Vasconcelos RO, Nunes CM, et al. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis. Vet Immunol Immunopathol. 201015;135:296\u2013302.", "ArticleIdList": ["20132994"]}, {"Citation": "Mao Y, Wang B, Xu X, Du W, Li W, Wang Y. Glycyrrhizic acid promotes M1 macrophage polarization in murine bone marrow-derived macrophages associated with the activation of JNK and NF-\u03baB. Mediators Inflamm. 2015;2015:372931. doi: 10.1155/2015/372931.", "ArticleIdList": ["10.1155/2015/372931", "PMC4668314", "26664149"]}, {"Citation": "Sarkar A, Saha P, Mandal G, Mukhopadhyay D, Roy S, Singh SK, et al. Monitoring of intracellular nitric oxide in leishmaniasis: its applicability in patients with visceral leishmaniasis. Cytometry A. 2011;79:35\u201345. doi: 10.1002/cyto.a.21001.", "ArticleIdList": ["10.1002/cyto.a.21001", "21182181"]}, {"Citation": "Singh N, Kumar R, Nyl\u00e9n S, Sacks D, Sundar S. The effect of TNF-\u03b1 neutralization on parasite load and cytokine production in human visceral leishmaniasis. Int J Infect Dis. 2016;45:62. doi: 10.1016/j.ijid.2016.02.180.", "ArticleIdList": ["10.1016/j.ijid.2016.02.180"]}, {"Citation": "Tumang MC, Keogh C, Moldawer LL, Helfgott DC, Teitelbaum R, Hariprashad J, et al. Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol. 1994;153:768\u2013775.", "ArticleIdList": ["8021511"]}, {"Citation": "Liu Z, Zhong JY, Gao EN, Yang H. Effects of glycyrrhizin acid and licorice flavonoids on LPS-induced cytokines expression in macrophage. Zhongguo Zhong Yao Za Zhi. 2014;39:3841\u20133845.", "ArticleIdList": ["25612451"]}, {"Citation": "Fu Y, Zhou E, Wei Z, Liang D, Wang W, Wang T, et al. Glycyrrhizin inhibits the inflammatory response in mouse mammary epithelial cells and a mouse mastitis model. The FEBS journal. 2014;281:2543\u20132557. doi: 10.1111/febs.12801.", "ArticleIdList": ["10.1111/febs.12801", "24698106"]}, {"Citation": "Bacellar O, D\u2019Oliveira A, Jr, Jeronimo S, Carvalho EM. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine. 2000;12:1228\u20131231. doi: 10.1006/cyto.2000.0694.", "ArticleIdList": ["10.1006/cyto.2000.0694", "10930301"]}, {"Citation": "Dayakar A, Chandrasekaran S, Kuchipudi SV, Kalangi SK. Cytokines: key determinants of resistance or disease progression in visceral leishmaniasis: opportunities for novel diagnostics and immunotherapy. Front Immunol. 2019;10:670. doi: 10.3389/fimmu.2019.00670.", "ArticleIdList": ["10.3389/fimmu.2019.00670", "PMC6459942", "31024534"]}]}], "History": [{"Year": "2020", "Month": "4", "Day": "7"}, {"Year": "2020", "Month": "7", "Day": "15"}, {"Year": "2020", "Month": "7", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "3", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "20"}], "PublicationStatus": "epublish", "ArticleIdList": ["32690108", "PMC7370265", "10.1186/s13071-020-04243-7", "10.1186/s13071-020-04243-7"]}}]}